Virus-specific antibodies have several roles in preventing and controlling virus infections. Antibodies can inhibit viral infection by virus neutralization. Antibodies can bind to virusinfected cells, and infected cells can then be killed by natural killer cells or monocytes/macrophages, which attach via Fc receptors (FcR) to antibodies bound to infected cells; this is referred to as antibody-dependent cell-mediated cytotoxicity. Antibodies bound to virus-infected cells may induce complement activation, and this can result in cell lysis. In addition, antibody bound to virus particles can enhance uptake of virus by FcR-bearing cells, such as antigen-presenting cells (APCs). This phenomenon, which is called antibody-dependent enhancement (ADE) of virus infection, has been described for several viruses, including influenza A virus (3, 6-8, 14, 15, 17, 23) .
Influenza A viruses undergo significant antigenic variation of their hemagglutinin (HA) and neuraminidase (NA) molecules, the major glycoproteins that are expressed on the viral surface. Two types of antigenic variation occur: antigenic shift and antigenic drift. Antigenic shift is a major antigenic change in the HA or the NA, and three different subtypes (HlNl, H2N2, and H3N2) of human influenza A viruses have been detected. Antigenic drift represents less marked antigenic changes in the HA and the NA that occur within a subtype.
We previously demonstrated by using reassortant viruses that antibodies to the HA and NA glycoprotein spikes of influenza virus enhance uptake of virus by FcR-bearing cells. We also reported that cross-reactive, nonneutralizing antibodies persisted and enhanced virus uptake of strains within the H3 subtype, despite the drift of neutralizing HA epitopes (24) . Ochiai et al. also reported that cross-reactive hemagglutination inhibition antibodies enhanced infection of influenza A virus strains within the Hi subtype (15) . Experiments using monoclonal antibodies (MAbs) specific to the HA of influenza A virus demonstrated that MAbs could be placed into three groups based on their neutralization (N) and infection-enhancing (E) activities: group I (N+E+), group II (N+E-), and group III (N±E+). The epitope recognized by each MAb was identified by using escape mutant viruses which had a single amino acid substitution compared with the parent virus (25) . The presence of ADE antibody has recently been demonstrated by using the sera of young children after primary infection with influenza A virus (6) . In the experiments described below, we used sera obtained from mice after primary influenza virus infection with A/PR/8/34 (A/PR; H1N1), A/Japan/305/57 (A/Japan; H2N2), or A/Port Chalmers/1/73 (A/PC; H3N2) and demonstrated the existence of subtype crossreactive antibodies that enhance uptake of virus but do not neutralize virus of a different subtype. Furthermore, we found that NA-specific MAbs obtained by immunizing with H2N2 subtype virus enhanced the uptake of H3N2 subtype virus strains. The presence of cross-subtype-reactive antibodies that enhance virus uptake into FcR-bearing cells, but do not neutralize virus, would result in augmented cross-subtypereactive T-and B-cell responses.
MATERUILS AND METHODS
Viruses. Influenza A virus strains A/PR (HlNl), A/Japan (H2N2), and A/PC (H3N2) were propagated in 9-day-old embryonated chicken eggs. Infected allantoic fluids were harvested on day 3 after infection, clarified by low-speed centrifugation, aliquoted, and stored at -80°C until use.
Cells. The macrophage-like P388D1 cell line (10) (24) .
Titration of neutralizing antibody. Neutralizing antibodies were determined in plaque assays in MDCK cells, using six-well tissue culture plates. Serially diluted mouse immune sera or ascites fluids were preincubated with 50 PFU of virus at 37°C for 1 h. After aspiration of medium from the well, 0.1 ml of the mixture of virus and antibody was added to each well and incubated at 37°C for 1 h with occasional agitation. Each well then received 3 ml of agar medium containing minimal essential medium, 0.1% D-glucose, 0.01% DEAE-dextran, 1% vitamins, 0.01 mg of trypsin per ml, and 1% agar. After 2 days of incubation in 5% CO2 at 37°C, 3 ml of 2% neutral red in PBS was overlaid onto the agar in each well. Plaques were counted after 10 h of incubation. The 90% plaque neutralizing antibody titers were calculated.
ELISA. Influenza A viruses were propagated in the allantoic fluids of embryonated chicken eggs, and concentrated virus was prepared by centrifugation of infected allantoic fluids at 18,000 rpm in a type 19 rotor for 4 h. The pellets were suspended in 5 ml of Hanks medium with 2% fetal calf serum. Further purification was obtained by centrifugation for 2 h at 24,000 rpm over a 20 and 65% sucrose gradient in a Beckman SW28 rotor. The white buffy layer between the sucrose was collected, and viral protein content was determined by the method of Lowry et al. (11) . Purified viruses were used as antigen for the enzyme-linked immunosorbent assay (ELISA). (Fig. 1) . The number of foci of A/PR antigen-positive cells was reduced at a serum dilution of 1:2 x 102 and was enhanced at dilutions from 1:2 x 103 to 1:2 x 104 by homologous serum (anti-A/PR serum). Serum from H2N2-immunized mice did not neutralize but did enhance uptake by A/PR at a dilution of 1:2. Serum from H3N2 virus-immune mice did not neutralize or enhance uptake by A/PR. Plaque neutralization titers confirmed these results ( Table 1) .
ADE of A/Japan (H2N2) virus infection. P388D1 cells were infected with A/Japan virus alone or after mixing with mouse polyclonal immune sera to A/PR, A/Japan, or A/PC (Fig. 2) . (Fig. 3) . The number of A/PC antigen-positive foci was reduced at a serum dilution of 1:2 x 10 and was enhanced at dilutions of 1:2 x 103 and 1:2 x 104 by the homologous (anti-A/PC) serum. The number of A/PC antigen-positive foci was also enhanced at dilutions from 1:2 to 1:2 x 102 by anti-A/Japan serum but was not reduced. Anti-A/PR serum neither reduced nor enhanced the number of A/PC antigen-positive foci. Plaque neutralization titers confirmed these results ( Table 1) .
Shift of neutralization or enhancement antigens on viruses of different subtypes. Table 1 human influenza A virus. Immune sera to each subtype virus neutralized the homologous virus but did not neutralize virus of other subtypes. We designated the dilution of serum at which the greatest increase in the number of antigen-positive foci was detected as the enhancement titer.
The enhancement titers of anti-A/PR were 2 x 104 with the anti-A/PR homologous virus (HlNl) and 2 with the H2N2 virus; anti-A/PR did not enhance uptake by the H3N2 virus. The enhancement titers of the anti-A/Japan serum were 2 x 104 with the homologous virus (H2N2) and 2 with the HINI and H3N2 viruses. The enhancement titers of the anti-A/PC serum were 2 x 103 with the homologous virus and 20 with the H2N2 virus.
An N2 neuraminidase-specific MAb augments uptake of virus infection by both A/Japan (H2N2) and A/PC (H3N2). We have previously shown by using recombinant viruses that antibodies to HA and NA enhance uptake of influenza A virus (25) . The present results demonstrate cross-reactivity of enhancement of virus uptake and the absence of detectable neutralization across subtypes ( The number of infected cells is shown in parentheses. Hi and H2 cross-reactive antibodies may be contained in the anti-A/PR and anti-A/Japan sera that we used and enhance uptake by virus of a different subtype at high concentrations of antibody ( Fig. 1 and 2 ). The overall amino acid sequence homology between the Ni and N2 proteins is 40% (5), and it is possible that antibodies to NA also contribute to the (Table 2 ). The function of NA in influenza virus infection is still unclear; however, one function of the NA is to remove sialic acid from the carbohydrate moiety of mucin, and this may facilitate virus release from the infected cells (27) . Generally, polyclonal antibodies to NA do not neutralize infectivity but do cause plaque size reduction; however, some MAbs to NA have been reported to neutralize virus infection (26, 27) . Antibody to NA reduced the pathology or mortality caused by influenza virus infection in mice or chickens (2, 19, 21) . With emergence of the H3 subtype in 1968 to 1969, the population had no immunity to the H3 HA during the H3N2 epidemic but had antibodies to the N2 because of previous infections with H2N2 viruses. Monto and Kendal reported that the frequency of infection, which was determined serologically by hemagglutinin inhibition in persons with high levels of preexisting naturally acquired antibody to N2 NA, was about one-half that of persons without antibody to N2 NA (13) . They concluded that antibody against the NA of the influenza virus prevented or modified infection when there was no preexisting anti-H3 HA antibody. We speculate that antibody to NA might also have increased the number of antigen-positive APCs, thereby augmenting activation of influenza A virus-specific T cells. It is interesting that MAb 73/1 neutralized only A/Japan but enhanced the uptake by both A/Japan and A/PC. We have previously demonstrated that enhancing activity persisted after neutralizing activity was lost, using several strains of virus within H3 subtype (24) . We also analyzed MAbs specific to HA of influenza A virus and demonstrated that those MAbs could be divided into three groups based on their N and E activities: group I (N+E+), group II (N+E-), and group III (N±E+±).
The epitope for each MAb was identified by using escape mutant viruses which had a single amino acid substitution compared with the parent virus (25) . MAb 73/1 recognizes region 2 of NA molecule, which is thought to encompass most of the top surface of the molecule (26) . Further analysis will be required to better define the epitope on NA recognized by MAb 73/1.
FcR-bearing cells such as macrophages and B cells are APCs for T lymphocytes (1, 18) . It was reported that T-cell responses were enhanced when FcR-bearing APCs were sensitized with antigen in the presence of antibody (4, 12, 20 
